Literature DB >> 12486182

Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect.

Samuel S Newton1, Johannes Thome, Tanya L Wallace, Yukihikko Shirayama, Lee Schlesinger, Norio Sakai, Jingshan Chen, Rachael Neve, Eric J Nestler, Ronald S Duman.   

Abstract

The cAMP response element-binding protein (CREB) is a critical integrator of neural plasticity that is responsive in a brain region-specific manner to a variety of environmental and pharmacological stimuli, including widely prescribed antidepressant medications. We developed inducible transgenic lines of mice that express either CREB or a dominant-negative mutant of CREB (mCREB) in forebrain regions and used these mice to determine the functional significance of this transcription factor in the learned helplessness paradigm, a behavioral model of depression. We also use a complementary viral-mediated gene transfer approach to directly test the effect of mCREB in the nucleus accumbens, a brain region important for motivation and reward. The results demonstrate that blockade of CREB by overexpression of mCREB in transgenic mice or by viral expression of mCREB in the nucleus accumbens produces an antidepressant-like effect, whereas overexpression of CREB in transgenic mice results in the opposite phenotype. In addition, mCREB expression was colocalized with and decreased the expression of prodynorphin in nucleus accumbens medium spiny neurons, and antagonism of dynorphin in the nucleus accumbens was sufficient to produce an antidepressant-like effect similar to that observed after blockade of CREB. Together, the results demonstrate that nucleus accumbens CREB-dynorphin influence behavior in the learned helplessness model and suggest that this signaling cascade may contribute to symptoms of depression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486182      PMCID: PMC6758459     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  125 in total

1.  Overexpression of CREB in the nucleus accumbens shell increases cocaine reinforcement in self-administering rats.

Authors:  Erin B Larson; Danielle L Graham; Rose R Arzaga; Nicole Buzin; Joseph Webb; Thomas A Green; Caroline E Bass; Rachael L Neve; Ernest F Terwilliger; Eric J Nestler; David W Self
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

2.  Analysis of target genes regulated by chronic electroconvulsive therapy reveals role for Fzd6 in depression.

Authors:  Bhavya Voleti; Keith Q Tanis; Samuel S Newton; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2011-09-19       Impact factor: 13.382

Review 3.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

4.  Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models.

Authors:  Heath D Schmidt; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

5.  Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats.

Authors:  Yonghui Li; Sa Li; Chuguang Wei; Huiying Wang; Nan Sui; Gilbert J Kirouac
Journal:  Psychopharmacology (Berl)       Date:  2010-07-20       Impact factor: 4.530

6.  cAMP response element binding protein phosphorylation in nucleus accumbens underlies sustained recovery of sensorimotor gating following repeated D₂-like receptor agonist treatment in rats.

Authors:  Alison K Berger; Thomas Green; Steven J Siegel; Eric J Nestler; Ronald P Hammer
Journal:  Biol Psychiatry       Date:  2010-10-30       Impact factor: 13.382

7.  Fluoxetine exposure during adolescence alters responses to aversive stimuli in adulthood.

Authors:  Sergio D Iñiguez; Lyonna F Alcantara; Brandon L Warren; Lace M Riggs; Eric M Parise; Vincent Vialou; Katherine N Wright; Genesis Dayrit; Steven J Nieto; Matthew B Wilkinson; Mary K Lobo; Rachael L Neve; Eric J Nestler; Carlos A Bolaños-Guzmán
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.

Authors:  Brendan M Walker; George F Koob
Journal:  Neuropsychopharmacology       Date:  2007-05-02       Impact factor: 7.853

Review 10.  Molecular and genetic substrates linking stress and addiction.

Authors:  Lisa A Briand; Julie A Blendy
Journal:  Brain Res       Date:  2009-11-10       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.